- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07453823
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals (myBIOM)
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals: a Randomized, Double-blind, Placebo-controlled Study
The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.
The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Sara Engel, PhD
- Número de telefone: +45 45 74 74 74
- E-mail: saen@novonesis.com
Estude backup de contato
- Nome: Emma Harrington
- E-mail: eharrington@atlantiatrials.com
Locais de estudo
-
-
Blackpool
-
Cork, Blackpool, Irlanda, T23 R50R
- Recrutamento
- Atlantia Clinical Trials Ltd
-
Contato:
- Emma Harrington
- Número de telefone: +353 (0)21 430 7442
- E-mail: eharrington@atlantiatrials.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Be able to give informed consent.
- Be between 45 to 70 years of age (inclusive).
- BMI <40.0 kg/m²
- Willing to maintain current level of physical activity and diet during the participation in the study.
- Experience ≤4 bowel movements per week within the month prior to screening
- Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-52 at screening.
- Willing to consume the study product daily for the duration of the study.
- Willing to eat the same meal the evening before visiting site (visit 2 to visit 5).
Participants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-52 during the two-week run-in period Record ≤8 bowel movements in the daily diary during the two-week run-in period
Exclusion Criteria:
-
Has a history of drug and/or alcohol abuse.
-
Has food allergies, or other issues with foods, that would preclude intake of the study products.
-
Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.
-
Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:
- diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)
- GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time.
- history of CVD
- uncontrolled hypertension
-
Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:
- systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1
- OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1
10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.
c. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including:
a. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics.
9. Planned major changes in lifestyle [i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling] during the duration of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Synbiotic
Synbiotic dietary supplement |
Synbiotic - Given daily for 56 days |
|
Comparador de Placebo: Placebo
Identical looking placebo consisting of maltodextrin |
Placebo - Given daily for 56 days |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Bifidobacterium abundance
Prazo: From baseline to end of intervention at 8 weeks
|
Change in total relative abundance of Bifidobacterium from baseline to 8 weeks assessed from fecal samples. Abundance is calculated based on shotgun metagenomic sequencing. |
From baseline to end of intervention at 8 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stool frequency
Prazo: From baseline to end of intervention at 8 weeks
|
Change in number of daily bowel movements from 2 weeks average prior to baseline to 2 weeks average prior to end of intervention. An increase is desirable. |
From baseline to end of intervention at 8 weeks
|
|
Fecal acetate
Prazo: From baseline to end of intervention at 8 weeks.
|
Change in fecal acetate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks.
|
|
Fecal propionate
Prazo: From baseline to end of intervention at 8 weeks.
|
Change in fecal propionate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks.
|
|
Fecal butyrate
Prazo: From baseline to end of intervention at 8 weeks
|
Change in fecal butyrate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks
|
|
Zonulin
Prazo: From baseline to end of intervention at 8 weeks
|
Change in serum zonulin from baseline to 8 weeks |
From baseline to end of intervention at 8 weeks
|
|
Lipopolysaccharide binding protein (LPS-BP)
Prazo: From baseline to end of intervention at 8 weeks
|
Change in plasma LPS-BP from baseline to 8 weeks |
From baseline to end of intervention at 8 weeks
|
|
Interleukin 6 (IL-6)
Prazo: From baseline to end of intervention at 8 weeks
|
Change in serum IL-6 from baseline to 8 weeks |
From baseline to end of intervention at 8 weeks
|
|
High-sensitivity C-Reactive Protein (hsCRP)
Prazo: From baseline to end of intervention at 8 weeks
|
Change in serum hsCRP from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks
|
|
Fecal Short-Chain Fatty Acids (SCFA)
Prazo: From baseline to end of intervention at 8 weeks
|
Change in composite measurement of fecal SCFAs panel with targeted metabolomics (GC-MSMS) from baseline to 8 weeks. Total composite is defined as: acetate + propionate + butyrate. |
From baseline to end of intervention at 8 weeks
|
|
Stool consistency
Prazo: From baseline to end of intervention at 8 weeks
|
Change in mean stool consistency assessed daily from 2 weeks prior to baseline to daily 2 weeks prior to end-of intervention. Stool consistency will be assessed by Bristol stool chart scale rated Type 1 (separate hard lumps) to Type 7 (watery, no solid pieces). An increase in stool consistency is desirable. |
From baseline to end of intervention at 8 weeks
|
|
Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) score
Prazo: From baseline to end of intervention at 8 weeks
|
Change in GSRS-IBS composite score from baseline to end-of-intervention visit. The GSRS-IBS questionnaire includes 13 items that measure the severity of IBS symptoms in five clusters (pain, bloating, constipation, diarrhea and early satiety) during the last seven days. A decrease is desirable. |
From baseline to end of intervention at 8 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recovery of probiotic strains
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Recovery and colonization of strains by strain specific qPCR of fecal samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Total relative abundance of Bifidobacterium
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
|
Change in total relative abundance of Bifidobacterium after 2 weeks of follow-up (no intervention) compared to effect after 3 weeks and 8 weeks of intervention. |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
|
|
Microbiome composition and taxonomic profiles
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Changes in gut microbiome composition and taxonomic profiling analyzed by shotgun metagenomic sequencing of fecal samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Microbiome functional profiling
Prazo: Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in gut microbiome functional profiling analyzed by shotgun metagenomic sequencing of fecal samples |
Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Plasma Metabolomics
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in blood metabolome as assessed by untargeted and targeted metabolomics from plasma samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Fecal metabolomics
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in fecal metabolome as assessed by untargeted and targeted metabolomics from fecal samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Bacterial HMO utilization genes
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Abundance development over time of HMO degradation and modification genes such as Glycosyl hydrolases, encoded by probiotic supplements and endogenous gut species |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
HMO concentration in blood and feces
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in HMO in plasma and fecal samples after 3 and 8 weeks of supplementation |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Fecal pH
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in pH assessed using a pH meter in fecal samples |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Inflammatory Biomarkers
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in inflammatory biomarkers measured in serum |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Cardiometabolic Biomarkers
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in cardiometabolic biomarkers |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Cognitive function measured by the Trails Making Test (Parts A & B)
Prazo: Baseline and end of intervention at 8 weeks
|
Change in cognitive function assessed using Trail Making Test (Parts A & B) |
Baseline and end of intervention at 8 weeks
|
|
Cognitive function measured by the Stroop Colour and Word Test
Prazo: Baseline and end of intervention at 8 weeks
|
Change in cognitive function assessed using the Stroop Colour and Word Test |
Baseline and end of intervention at 8 weeks
|
|
Cognitive function measured by the Symbol Digit Modalities Test (SDMT)
Prazo: Baseline and end of intervention at 8 weeks
|
Change in cognitive function assessed using the Symbol Digit Modalities Test (SDMT) |
Baseline and end of intervention at 8 weeks
|
|
Health-related Quality of Life
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in health-related quality of life assessed by Short Form-36 (RAND SF-36) |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Gastrointestinal Symptoms Measured by the GSRS-IBS Total Score
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in gastrointestinal symptoms by assessing the Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS). The outcome reflects the total composite score. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
GSRS-IBS Pain Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
|
Change in the gastrointestinal symptom pain assessed using GSRS-IBS subscale for Pain. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
|
|
GSRS-IBS Bloating Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom bloating assessed using GSRS-IBS subscale for bloating. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
GSRS-IBS Constipation Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom constipation assessed using GSRS-IBS subscale for constipation. A decrease is desirable |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
GSRS-IBS Diarrhea Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom Diarrhea assessed using GSRS-IBS subscale for Diarrhea. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
GSRS-IBS Early Satiety Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom early satiety assessed using GSRS-IBS subscale for early satiety. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
Protein Composite Score
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in protein composite score measured using OLINK Reveal panel |
Baseline, 3 weeks and end of intervention at 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Martin Buckley, Professor, Atlantia Clinical Trials Ltd
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HHB-GI-2406
- ECM4(i)11/12/2025 (Outro identificador: Clinical Research Ethics Committee of the Cork Teaching Hospitals)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .